NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









T-CURX GmbH

T-CURX GmbH

Private
WürzburgHealthcare & Life Scienceshttps://t-curx.com/

Last Round

Series A

Dec 17, 2025

Total Funding Raised

$20.8M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

T-CURX GmbH is a biotechnology company that develops and commercializes next-generation CAR-T cell therapies for cancer using proprietary non-viral, transposon-based gene transfer technology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Data as a Service

AI Layer

Non-AI

Keywords

CAR-T cell therapynon-viral gene transfercell engineeringoncology therapeuticscell-based immunotherapylipid nanoparticleLNPSleeping Beauty transposonnext-gen cell therapybiotech licensinggene delivery platformcell therapy manufacturingprecision medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

T-CURX GmbH Comparables

Compare T-CURX GmbH with similar companies based on industry and business-model similarity.

T-CURX GmbH comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
A-SEEDS Co., Ltd.
83%
Integra Therapeutics
81%
Carla BioTherapeutics
79%

T-CURX GmbH Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series ADec 17, 2025
GrantDec 15, 2020
GrantJan 2, 2018

Key People

Founding team and executive leadership

Ulf Grawunder

Chief Executive Officer And Co-founder

Founding Team

T-CURX GmbH Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 24, 2026

    Grew 46% QoQ, from 13 to 19 employees.

  • Sep 9, 2025

    Partnered with Kytopen and Fraunhofer IZI to develop advanced cell therapies.

T-CURX GmbH Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

T-CURX GmbH Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about T-CURX GmbH's valuation, stock price, and market status.

Firmographic Details

HeadquartersWürzburg
Employee Range20
Year Founded2017
Last FundingDec 17, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.